ストックスクリーナーアプリを入手
3.55
3.27%
-0.12
アフターアワーズ：
3.56
0.01
+0.28%
前日終値:
$3.67
開ける：
$3.68
24時間の取引高:
153.52K
Relative Volume:
0.69
時価総額：
$138.14M
収益：
$1.50M
当期純損益:
$-81.41M
株価収益率:
-0.5453
EPS:
-6.51
ネットキャッシュフロー:
$-43.75M
1週間 パフォーマンス:
-22.99%
1か月 パフォーマンス:
+38.67%
6か月 パフォーマンス:
+11.29%
1年 パフォーマンス:
+96.13%
1日の値動き範囲:
$3.48
$3.7079
1週間の範囲:
$3.40
$4.79
52週間の値動き範囲:
$1.32
$5.00
Leap Therapeutics Inc Stock (LPTX) Company Profile
名前
Leap Therapeutics Inc
セクター
電話
617 252 4343
住所
47 THORNDIKE STREET, CAMBRIDGE, MA
Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-10-04 | 開始されました | Mizuho | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2020-06-29 | 開始されました | Piper Sandler | Overweight |
| 2020-02-11 | 開始されました | Robert W. Baird | Outperform |
| 2019-11-15 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2019-09-13 | 再開されました | Raymond James | Outperform |
| 2017-03-07 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Leap Therapeutics Inc (LPTX) 最新ニュース
Sermonix Pharmaceuticals’ Lasofoxifene Is Well Tolerated, - GlobeNewswire
DKN-01 With Tislelizumab and Chemotherapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma - The ASCO Post
Leap Therapeutics, Inc. (NASDAQ:LPTX) Sees Large Decline in Short Interest - MarketBeat
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Payment processor Finix secures $75m in Series C funding - Electronic Payments International
Astellas nabs class-first FDA approval for CLDN18.2 gastric cancer med Vyloy - FiercePharma
Dow Jones notches new record, chip stocks leap higher - Yahoo Finance
Marshall Wace LLP Acquires New Stake in ChromaDex Co. (NASDAQ:CDXC) - Defense World
Profire Energy, Inc. (NASDAQ:PFIE) Shares Sold by Marshall Wace LLP - Defense World
Marshall Wace LLP Makes New Investment in Vivid Seats Inc. (NASDAQ:SEAT) - Defense World
Venous Leg Ulcers Treatment Market value, Innovations Driving Market Evolution (2024-2036) - Third Eye News
Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients - The Malaysian Reserve
LPTXLeap Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Venous Leg Ulcers Treatment Market Growth, Size, Research Report and Forecast (2024-2034) - Talented India
Leap Therapeutics (NASDAQ:LPTX) Share Price Passes Below 50 Day Moving Average of $2.58 - MarketBeat
Biliary Tract Cancer Pipeline Analysis 2024: FDA Approvals - openPR
TSX Communication Services Capped Index (TTTS) QuotePress Release - The Globe and Mail
Simplify Asset Management Inc. Has $1.24 Million Stock Position in Leap Therapeutics, Inc. (NASDAQ:LPTX) - MarketBeat
Simplify Asset Management Inc. Buys 255,293 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) - Defense World
Meiji Yasuda Asset Management Co Ltd. Has $1.22 Million Stock Position in Hilton Worldwide Holdings Inc. (NYSE:HLT) - Defense World
Commonwealth Equity Services LLC Boosts Position in AllianzIM U.S. Large Cap Buffer10 Sep ETF (NYSEARCA:SEPT) - Defense World
Newmark Security (LON:NWT) Stock Price Crosses Above Two Hundred Day Moving Average of $91.75 - Defense World
How Analyst Ratings Affect Leap Therapeutics Inc Inc. (LPTX) Price Performance - The InvestChronicle
Second generation of I-SPY 2 TRIAL design is driving the “precise” in precision medicine - Yahoo Finance
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story - Simply Wall St
Lilly adds to genetic meds push with Genetic Leap alliance - pharmaphorum
Eli Lilly partners with AI-focused Genetic Leap to develop RNA-based drugs - Yahoo Finance
Vera Therapeutics (NASDAQ:VERA) vs. Pivotal Therapeutics (OTCMKTS:PVTTF) Financial Analysis - Defense World
Global Gastric Cancer Diagnostics Market is Expected to Expand at a CAGR of ~7% by 2030 | DelveInsight - PR Newswire UK
ORKA Stock Price and Chart — NASDAQ:ORKA - TradingView
Lululemon Athletica (NASDAQ:LULU) Price Target Lowered to $326.00 at Morgan Stanley - Defense World
Farther Finance Advisors LLC Has $1.20 Million Stake in Paychex, Inc. (NASDAQ:PAYX) - Defense World
Laramide Resources Ltd. (TSE:LAM) Director Buys C$10,200.00 in Stock - Defense World
Rothschild Investment LLC Buys Shares of 8,904 Capital Group Growth ETF (NYSEARCA:CGGR) - Defense World
Picton Mahoney Asset Management Takes $71,000 Position in American Woodmark Co. (NASDAQ:AMWD) - Defense World
Rothschild Investment LLC Makes New Investment in iShares Core MSCI Europe ETF (NYSEARCA:IEUR) - Defense World
Farther Finance Advisors LLC Has $1.36 Million Stake in McKesson Co. (NYSE:MCK) - Defense World
Intel Co. (NASDAQ:INTC) Shares Purchased by Farther Finance Advisors LLC - Defense World
Rothschild Investment LLC Takes Position in BlackRock MuniHoldings Quality Fund II, Inc. (NYSE:MUE) - Defense World
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Trims Stock Holdings in Universal Health Services, Inc. (NYSE:UHS) - Defense World
Allspring Global Investments Holdings LLC Sells 103,605 Shares of Wabash National Co. (NYSE:WNC) - Defense World
Leap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest Update - MarketBeat
Sermonix Pharmaceuticals Completes Enrollment of Phase 2 - GlobeNewswire
Atossa and Quantum Leap dose first subject in breast cancer therapy trial - Yahoo Finance
Openwater Achieves Quantum Leap in Medicine: Harnesses Light, Sound, and Electromagnetics to Diagnose and Treat Diseases at Cellular Level - Yahoo Finance
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer - ForexTV.com
Vanguard Group Inc. Buys 457,904 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) - MarketBeat
AstraZeneca (LON:AZN) Stock Price Crosses Above 200-Day Moving Average of $11,535.34 - Defense World
Vanguard Group Inc. Acquires 156,044 Shares of Priority Technology Holdings, Inc. (NASDAQ:PRTH) - Defense World
Analysts Issue Forecasts for Leap Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:LPTX) - MarketBeat
Q3 2024 EPS Estimates for MiNK Therapeutics, Inc. (NASDAQ:INKT) Boosted by Analyst - Defense World
Leap Therapeutics Inc (LPTX) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):